ADRIFORANT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H22N6
Molecular Weight	262.354
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN[C@@H]1CCN(C1)C2=NC(N)=NC(NCC3CC3)=C2

InChI

InChIKey=ISBHYKVAFKTATD-SNVBAGLBSA-N

InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H22N6
Molecular Weight	262.354
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:22:17 UTC 2023` Edited by `admin` on `Sat Dec 16 10:22:17 UTC 2023`
Record UNII	D65H9YE9VU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADRIFORANT

Official Name

English

ZPL389-NX

Code

English

NVP-ZPL389-NX

Code

English

N4-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine

Systematic Name

English

ZPL-389-NX

Code

English

PF-3893787

Code

English

Adriforant [WHO-DD]

Common Name

English

PF-03893787

Code

English

ADRIFORANT [USAN]

Common Name

English

adriforant [INN]

Common Name

English

2,4-PYRIMIDINEDIAMINE, N4-(CYCLOPROPYLMETHYL)-6-((3R)-3-(METHYLAMINO)-1-PYRROLIDINYL)-

Systematic Name

English

ZPL-3893787

Code

English

ZPL-389

Code

English

Code System Code Type Description

EVMPD

SUB194074

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

FDA UNII

D65H9YE9VU

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

PUBCHEM

24745335

Created by admin on Sat Dec 16 10:22:18 UTC 2023 , Edited by admin on Sat Dec 16 10:22:18 UTC 2023

PRIMARY

NCI_THESAURUS

C169765

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

USAN

HI-100

Created by admin on Sat Dec 16 10:22:18 UTC 2023 , Edited by admin on Sat Dec 16 10:22:18 UTC 2023

PRIMARY

ChEMBL

CHEMBL1915540

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

INN

10855

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

CAS

943057-12-3

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

DRUG BANK

DB15027

Created by admin on Sat Dec 16 10:22:17 UTC 2023 , Edited by admin on Sat Dec 16 10:22:17 UTC 2023

PRIMARY

SMS_ID

100000178346

Created by admin on Sat Dec 16 10:22:18 UTC 2023 , Edited by admin on Sat Dec 16 10:22:18 UTC 2023

PRIMARY

Related Record Type Details


					539B0275OU

HISTAMINE H4 RECEPTOR

TARGET -> INHIBITOR


					D0DVK27O02

ADRIFORANT TARTRATE DIHYDRATE

SALT/SOLVATE -> PARENT

Related Record Type Details


					D65H9YE9VU

ADRIFORANT

ACTIVE MOIETY

Comments:

Originator: Pfizer; Developer: Pfizer, Ziarco; Class: Anti-inflammatory, Antiasthmatic, Pyrimidine, Pyrrolidine, Small molecule; Mechanism of Action: Histamine H4 receptor antagonist; Highest Development Phases: Phase II for Atopic dermatitis, Plaque psoriasis, Discontinued for Asthma; Most Recent Event: 13 Jun 2016 Final efficacy data from a phase IIb trial in Atopic dermatitis released by Ziarco Pharma, 16 May 2016 Ziarco Pharma plans a phase IIb trial in Atopic dermatitis, 16 May 2016 Top-line efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Ziarco Pharma